A Study to Evaluate Nivolumab in the Treatment of Early Stage Esophageal or Gastroesophageal Cancer
NCT05780736 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 33
Last updated 2024-09-25
Summary
The purpose of this study is to describe the effectiveness and use of nivolumab after surgery in participants with early stage (Stage II/III) Esophageal Cancer/Gastroesophageal Junction Cancer (EC/GEJC).
Conditions
- Esophageal Carcinoma
- Gastroesophageal Junction Carcinoma
Sponsors & Collaborators
-
PPD Development, LP
collaborator INDUSTRY - lead INDUSTRY
Principal Investigators
-
Bristol-Myers Squibb · Bristol-Myers Squibb
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2023-08-04
- Primary Completion
- 2024-08-23
- Completion
- 2024-08-23
Countries
- United States
- Germany
Study Locations
More Related Trials
-
Immune Checkpoint Therapy With Nivolumab Esophageal Squamous Cell Carcinoma
NCT03278626 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Study of Pembrolizumab (MK-3475) in Previously-Treated Participants With Advanced Carcinoma of the Esophagus or Esophagogastric Junction (MK-3475-180/KEYNOTE-180)
NCT02559687 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Neoadjuvant Nivolumab or Placebo Plus Chemotherapy Followed by Surgery and Adjuvant Treatment in Subjects With Resectable ESCC
NCT05213312 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Taladegib, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Localized Esophageal or Gastroesophageal Junction Cancer
NCT02530437 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Phase II Trial for Patients With Loco-Regional Esophageal Carcinoma
NCT00570531 ·Status: TERMINATED ·Phase: PHASE2
-
A Study of Participants With Squamous Cell Oesophageal Carcinoma Receiving Nivolumab as Part of an Early Access to Medicines Scheme (EAMS) Program in the United Kingdom
NCT04936399 ·Status: COMPLETED
-
Study of Pembrolizumab (MK-3475) Versus Investigator's Choice Standard Therapy for Participants With Advanced Esophageal/ Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)
NCT02564263 ·Status: COMPLETED ·Phase: PHASE3
-
Molecularly Tailored Therapy for Patients With Metastatic Cancer of the Esophagus and Stomach
NCT02358863 ·Status: TERMINATED ·Phase: NA
-
A Multicenter Open-label Phase II Trial to Evaluate Nivolumab and Ipilimumab for 2nd Line Therapy in Elderly Patients With Advanced Esophageal Squamous Cell Cancer
NCT03416244 ·Status: COMPLETED ·Phase: PHASE2
-
Epacadostat and Pembrolizumab Before Surgery in Treating Participants With Stage II-III Esophageal or Gastroesophageal Cancer
NCT03592407 ·Status: WITHDRAWN ·Phase: PHASE2
-
A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer
NCT06123338 ·Status: RECRUITING ·Phase: PHASE2
-
Prognostic Analysis of Esophageal Cancer with Complete Pathological Response After Neoadjuvant Therapy
NCT06889402 ·Status: NOT_YET_RECRUITING
-
Pembrolizumab, Radiotherapy, and Chemotherapy in Neoadjuvant Treatment of Malignant Esophago-gastric Diseases (PROCEED)
NCT03064490 ·Status: COMPLETED ·Phase: PHASE2
-
Optimizing Neoadjuvant Treatment Regimens for Locally Advanced Esophageal Squamous Cell Carcinoma
NCT06907602 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
Phase II Trial of Neoadjuvant Pembrolizumab for Patients With Early Stage Gastroesophageal Adenocarcinoma
NCT04089904 ·Status: TERMINATED ·Phase: PHASE2
-
Chemoradiation and Pembrolizumab Followed by Pembrolizumab and Lenvatinib Before Surgery for the Treatment of Non-metastatic Esophageal or Esophageal/Gastroesophageal Junction Cancer
NCT04929392 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Pembrolizumab and Chemoradiotherapy for the Treatment of Unresectable Gastroesophageal Cancer
NCT04522336 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Temozolomide + Nivolumab in MGMT Methylated Oesophagogastric Cancer
NCT04984733 ·Status: COMPLETED ·Phase: PHASE2
-
Phase I/II Evaluation of a Cancer Lysate Vaccine and Montanide(R) ISA-51 VG With Entinostat and Nivolumab as Adjuvant Therapy Following Chemoradiation Therapy With or Without Surgery for Locally Advanced Esophageal Cancer
NCT05898828 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
Use of Cetuximab for Unresectable or Metastatic Esophageal and Gastric Cancer
NCT00130689 ·Status: COMPLETED ·Phase: PHASE2
-
Epacadostat and Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Junction or Gastric Cancer
NCT03196232 ·Status: COMPLETED ·Phase: PHASE2
-
Pembrolizumab in Refractory Advanced Esophageal Cancer
NCT02971956 ·Status: COMPLETED ·Phase: PHASE2
-
S0414 Cetuximab, Combo Chemo, and RT in Locally Advanced Esophageal Cancer
NCT00109850 ·Status: TERMINATED ·Phase: PHASE2
-
Study of Nivolumab in Unresectable Advanced or Recurrent Esophageal Cancer
NCT02569242 ·Status: COMPLETED ·Phase: PHASE3
-
Study of Cetuximab and Bevacizumab in Cancer of the Esophagus After Failure of Patient's First Therapy
NCT00636298 ·Status: WITHDRAWN ·Phase: PHASE2